Protego Biopharma closed a $130 million Series B to advance PROT‑001, an oral small‑molecule kinetic stabilizer targeting lambda light chains in AL amyloidosis, into a pivotal trial slated to begin in H2 2026. The financing, described as oversubscribed, will support clinical development and broader program expansion into other protein‑misfolding diseases. Protego’s approach — small molecules that stabilize misfolding proteins rather than removing them — is framed as complementary to plasma‑cell–directed therapies and may enable tandem regimens. AL amyloidosis is a rare, often fatal disease where stabilizing pathogenic light chains could slow organ deposition and dysfunction.